Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1

Langenbeck's Archives of Surgery

Volumn 386, Issue 8, 2002, Pages 558-569

  Åkerström, Göran ^a   Hessman, Ola ^a   Skogseid, Britt ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endocrine pancreatic tumors; Indications; Multiple endocrine neoplasia type 1; Surgery

Indexed keywords

BIOCHEMICAL MARKER;

CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENDOSCOPY; FOLLOW UP; GASTRINOMA; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS RESECTION; PANCREAS TUMOR; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REOPERATION; REVIEW; SCREENING TEST; TREATMENT INDICATION; ZOLLINGER ELLISON SYNDROME;

ADENOMA; DUODENAL NEOPLASMS; GLUCAGONOMA; HUMANS; HYPERPARATHYROIDISM; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036210062     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-001-0274-6     Document Type: Review

References (69)

1. Familial multiple endocrine andenoma-peptic ulcer complex
2. Multiple endocrine neoplasia type 1 (MEN 1)
3. Aldosterone-secreting adrenal adenoma as part of the multiple endocrine neoplasia type 1 (MEN 1): Loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN 1 locus
4. Thymic carcinoids in multiple endocrine neoplasia type 1
5. Multiple endocrine neoplasia syndromes
6. The natural history of MEN 1, which may be highly unrecognized rather than highly uncommon
7. Genetic aspects of adenomatosis of endocrine glands
8. Multiple endocrine neoplasia typ 1 gene maps to chromosome 11 and is lost in insulinoma
9. Positional cloning of the gene for multiple endocrine neoplasia type 1
10. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders
11. MEN 1 gene mutations in 12 MEN 1 families and their associated tumors
12. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: Surgery or surveillance?
13. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
14. Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism
15. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type B signaling
16. Multiple allelic deletions and intratumoral genetic heterogeneity in MEN 1 pancreatic tumors
17. MEN 1 pancreas: A histological and immunohistochemical study
18. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type 1: An immunocytochemical study of nine patients
19. Pancreatic tumors in multiple endocrine neoplasia type 1: Clinical presentation and surgical treatment
20. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1
21. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome
22. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type 1
23. Pancreas endocrine tumors in multiple endocrine neoplasia type 1
24. Surgical treatment of endocrine pancreatic lesions in MEN 1
25. Duodenal gastrinoma: The solution to the pancreatic paradox
26. Multiple endocrine neoplasia type 1: A ten-year prospective screening study in four kindreds
27. Islet cell tumor metastasis in multiple endocrine neoplasia type 1: Correlation with primary tumor size
28. Lethality of multiple endocrine neoplasia type 1
29. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1
30. Findings and long-term results of parathyroid surgery in multiple endocrine neoplasia type 1
31. Screening for the multiple endocrine neoplasia type 1 syndrome: A study of 11 kindreds in the Netherlands
32. Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1
33. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1
34. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: Can it be predicted by preoperative tumor localization?
35. Operative tumour yield obviates preoperative pancreatic localization in multiple endocrine neoplasia type 1
36. Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors
37. Role of endoscopic ultrasonography in the localization of insulinomas and gastrinomas
38. Endoscopic ultrasonography and somatostatin receptor scintigraphy in preoperative localization of insulinomas and gastrinomas
39. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy
40. Usefulness of selective arterial secretion injection test for localization of gastrinoma in the Zollinger-Ellison syndrome
41. Endoscopic ultrasonography of the pancreas
42. Curative resection of microgastrinomas based on the intraoperative secretin test
43. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type 1
44. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1
45. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome
46. Current concept in the surgical management of multiple endocrine neoplasia type 1 pancreatico-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both
47. Microgastrinomas of the duodenum: A cause of failed operations for the Zollinger-Ellison syndrome
48. The surgical treatment of gastrinoma in MEN 1 syndrome patients
49. Surgical treatment of the endocrine pancreas and the Zollinger-Ellison syndrome in the MEN 1 syndrome
50. Location, incidence and malignant potential of duodenal gastrinomas
51. Clinicopathological characteristics of duodenal microgastrinomas
52. Duodenal gastrinomas, duodenotomy and duodenal exploration in the surgical management of Zollinger-Ellison syndrome
53. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient
54. Surgery to cure the Zollinger-Ellison syndrome
55. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome
56. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1
57. Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study
58. Surgery for Zollinger-Ellison syndrome alters the natural history of gastrinoma
59. The gastrinoma triangle: Operative implications
60. Role of pancreaticoduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome
61. Surgical management of hyperinsulinism in the multiple endocrine neoplasia, type 1 syndrome
62. Surgical management of insulinoma associated with multiple endocrine neoplasia type 1
63. The surgical management of patients with multiple endocrine neoplasia type 1
64. Insulinomas associated with multiple endocrine neoplasia type 1: The need for a different surgical approach
65. Intraoperative ultrasonographic localization of islet cell tumors: A prospective comparison to palpation
66. Total pancreatectomy in the MEN 1 syndrome
67. Are patients with multiple endocrine neoplasia type 1 prone to premature death?
68. Surgical strategy for large or malignant endocrine pancreatic tumors